reviewed april 2026|next review october 2026|88 physicians psi has verified|1050 published studies
TB-500
TB-500 is a synthetic fragment of thymosin beta-4, a protein naturally produced in nearly every cell in the body that regulates cell migration and tissue repair. It is not an approved medicine.
Evidence landscape: 1050 published studies
1,050 published items: 167 animal studies and 13 human studies on the parent protein thymosin beta-4. A notable research base for a compound with no commercial FDA development program.
- 13 Human
- 167 Animal
- 20 Reviews
- 850 Other research
Not a prescription medicine in the U.S. A doctor cannot currently have it prepared through any pharmacy, specialty or otherwise. The legal rules are expected to change.
Almost all published human data is on the parent protein thymosin beta-4, not on TB-500 specifically. That means a first-in-human safety study of the parent protein has been completed, which is not the same as showing TB-500 itself works for any condition in people.
More than 1,000 published studies cover multiple tissue types, but clinical development has stalled at early-phase trials. No large late-stage human trial program is currently active for any indication.
PSI Assessment
Over a thousand studies have looked at TB-500 for tissue repair, across skin, tendon, muscle, and heart tissue, and the results in animal models are consistently positive. That is an unusually large research base for a compound that is not an approved medicine. But almost none of that work has been done in people. And here is the part most sources leave out: nearly all the human research that does exist was done on thymosin beta-4, the full-length natural protein that TB-500 is a small piece of. Whether a piece of the protein works the same way as the whole thing has never been tested.
Twenty years of research. A thousand studies. And the hardest question, does a fragment behave like the whole protein, has never actually been tested.
The mechanism is well characterized and published in Nature: TB-500 binds to actin, a protein every cell uses to move and rebuild, which promotes cell migration toward injury sites and new blood vessel formation. That universal mechanism is why repair effects show up across so many tissue types rather than being limited to one organ. The critical open question is whether TB-500 the synthetic fragment produces the same effects as thymosin beta-4 the full protein. Most of the published research, including the Nature cardiac data, studied the parent protein.
What the evidence supports
Tissue repair effects show up consistently in animal models across skin, tendon, muscle, and heart tissue. The reason the range is so broad is that the mechanism touches something universal: a protein called actin that every living cell uses to move and rebuild itself. The tissue-type range is not a coincidence. It is the signature of a pathway that operates in most repairing tissue.
What is not yet established
Whether TB-500 the fragment matches thymosin beta-4 the whole protein. Whether any of the animal results translate to humans at meaningful doses. Whether the cardiac results would hold up in a human trial. None of these questions has a published answer.
Research Evidence
The three findings below are what a thousand studies across four tissue types come down to.
Evidence by condition
Evidence dimensions available for each condition TB-500 has been studied for. For a research peptide, consistent mechanism + animal evidence + any human evidence + replication across labs is the meaningful evidence signature.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Wound Healing | ||||
| Cardiac Recovery | ||||
| Musculoskeletal Repair | ||||
| Neuroprotection | ||||
| Hair Growth |
Animal studies show tissue repair effects across at least four tissue types: cardiac, dermal, corneal, and musculoskeletal. Few regenerative peptides have this breadth of animal study evidence.
This breadth is consistent with an actin-based mechanism, which is universal to cell migration rather than tissue-specific. It also means the research base is broad but thin per tissue: no single indication has been pursued to Phase III.
The mechanism is well characterized. TB-500 binds to a cellular protein called actin, which lets cells reorganize and migrate toward injury sites. It also promotes new blood vessel formation and reduces inflammatory signaling.
Having a clear mechanism is unusual for a research peptide. It means the biological plausibility for tissue repair is stronger than average, even though human confirmation is limited.
Cardiac repair data published in Nature in 2007 showed that thymosin beta-4 activates cells in the outer layer of the heart and promotes new blood vessel growth in mice after a heart attack.
Publication in Nature gives TB-500 stronger academic credibility than most research peptides. But no human cardiac trial has followed, and the Nature paper studied the parent protein, not TB-500.
13 Human|167 Animal|20 Reviews
View all 1050 indexed studiesHow TB-500 Works
TB-500 is a 17-amino-acid synthetic peptide, which means it is a short chain of building blocks that normally make up proteins. It is a fragment of thymosin beta-4, a 43-amino-acid protein naturally produced in nearly every cell in the body.
TB-500 helps cells move to where they are needed. Think of it as improving the body's ability to dispatch repair crews to an injury site faster. It also dials down inflammation, which can otherwise slow the healing process.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
TB-500 binds to a cellular protein called actin, which regulates how cells reorganize their internal skeleton during migration. By controlling actin, TB-500 helps cells move toward injury sites and promotes new blood vessel formation, a process called angiogenesis. It also reduces inflammatory signaling by lowering cytokines including tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6). This systemic mechanism, acting on a universal cellular protein, is what allows TB-500 to show effects across diverse tissue types rather than being localized to a specific organ.
What is TB-500 being studied for?
Researchers are studying TB-500 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for TB-500 overall. This means a compound can have human studies for one condition but only animal data for another.
Wound Healing
·Animal StudiesAnimal studies show TB-500 accelerates wound closure and promotes new blood vessel formation at wound margins. Some limited human data exists for the parent protein thymosin beta-4 in topical ophthalmic and skin applications.
Limitations: Most wound healing data comes from animal models. Human trials of the parent protein exist but are small and early-phase. No controlled TB-500-specific human wound healing trial has been published.
Cardiac Recovery
·Animal StudiesIn animal models, thymosin beta-4 reduced heart tissue damage and improved cardiac function after myocardial infarction. The Nature paper from 2007 is the highest-profile cardiac finding.
Limitations: All controlled cardiac data is from animal models. A small clinical evaluation in acute MI patients has been reported but without Phase III confirmation. Translation to routine human cardiology is not established.
Musculoskeletal Repair
·Animal StudiesRodent studies show accelerated muscle recovery after crush injury. Equine studies reported improved tendon healing in racehorses, which is the most clinically adjacent setting in the published record.
Limitations: Equine data is the most clinically relevant nonhuman evidence but is still not human. Dosing, timing, and route of administration in humans are not established.
Neuroprotection
·PreclinicalA small number of animal studies suggest thymosin beta-4 may protect brain tissue after injury. The evidence base is early and limited.
Limitations: Only a small number of animal studies exist. No human neurological studies have been conducted. Mechanisms in the brain are not fully characterized.
Hair Growth
·PreclinicalAnimal studies show thymosin beta-4 promotes hair follicle stem cell migration and new hair growth, observed incidentally in wound healing research.
Limitations: No human hair growth studies exist. The effect was noted as a secondary observation, not as a primary research endpoint.
Safety and Regulatory Status
FDA Status: Not approved in the United States for any indication. A doctor cannot currently write a prescription for it.
Legal access: Currently a doctor cannot have TB-500 prepared through a specialty pharmacy, where a licensed pharmacist ordinarily prepares a medicine from ingredients for an individual patient. Following a February 2026 HHS announcement, that access route is expected to be restored, pending the final FDA update.
International status: No known non-US regulatory approval. The World Anti-Doping Agency classifies thymosin beta-4 as a prohibited substance in sport, meaning competitive athletes cannot use it.
No significant adverse effects have been reported in animal studies at therapeutic doses. Early-phase human trials of the parent protein thymosin beta-4 showed a favorable safety profile at the doses tested, but human safety data specific to TB-500 is extremely limited. TB-500 is on the World Anti-Doping Agency (WADA) prohibited list, meaning competitive athletes cannot use it.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a TB-500 discussion.
Comparison and Related Research
TB-500 is most often compared with other tissue-repair and regenerative peptides, especially BPC-157 with which it is frequently paired in recovery protocols. The comparisons below break down how each compound differs in mechanism, evidence base, and research focus.
Head-to-head comparisons
Full research comparisons covering TB-500 and another peptide side by side.
TB-500 vs BPC-157
Side-by-side research comparison of BPC-157 and TB-500 for tissue repair. Mechanisms, evidence, and limitations from published research.
View full comparisonTB-500 vs BPC-157
Three-way comparison of BPC-157, TB-500, and GHK-Cu for tissue repair and regeneration research. Mechanisms, evidence levels, study types, and key limitations analyzed.
View full comparisonTB-500 vs GHK-Cu
TB-500 targets deep tissue through actin regulation. GHK-Cu targets skin through collagen. Evidence-graded comparison of two healing peptides.
View full comparisonTB-500 vs Thymosin Beta-4
TB-500 is a fragment of Thymosin Beta-4. Most research uses the full protein. What the difference means for evidence and clinical use.
View full comparisonResearch blends
Some researchers and clinicians study TB-500 in combination with other peptides. These blends are covered in dedicated pages with their own evidence assessments.
BPC-157 and TB-500 Blend (Wolverine Stack)
BPC-157 targets localized healing through blood vessel formation. TB-500 acts systemically through cell migration. The two mechanisms do not overlap, which is why researchers study them together.
View blend pageBPC-157, TB-500, and GHK-Cu Blend (Glow Stack)
Adds GHK-Cu, a copper peptide studied for collagen production, skin remodeling, and hair follicle support.
View blend pageBPC-157, TB-500, GHK-Cu, and KPV Blend (KLOW Stack)
Adds KPV, a peptide studied for reducing inflammatory signaling.
View blend pageRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.High-impact study in Nature showing that thymosin beta-4 activates repair cells in the outer layer of the adult mouse heart and promotes new blood vessel growth after injury.Smart N et al., 2007 in Nature. View on PubMed
- 2.Comprehensive review of the biology of thymosin beta-4 and early clinical applications in wound healing and ophthalmology.Goldstein AL et al., 2012 in Expert Opin Biol Ther. View on PubMed
- 3.Review of how thymosin beta-4 accelerates corneal wound closure in animal models, with reference to early human topical studies.Sosne G et al., 2015 in Ann N Y Acad Sci. View on PubMed
- 4.Animal study showing that both full-length thymosin beta-4 and a synthetic fragment containing its actin-binding domain accelerate skin wound healing in diabetic and aged mice.Philp D et al., 2006 in FASEB J. View on PubMed
- 5.Foundational animal study demonstrating that thymosin beta-4 promotes new blood vessel formation and accelerates wound closure in rodent skin injury models.Malinda KM et al., 1999 in J Invest Dermatol. View on PubMed
- 6.First-in-human Phase I study of recombinant human thymosin beta-4, the parent protein of TB-500. Small placebo-controlled study evaluating safety and pharmacokinetics.Zhu J et al., 2021 in Int J Clin Pharmacol Ther. View on PubMed
- 7.Translational study combining mouse myocardial infarction experiments with an early clinical evaluation of recombinant thymosin beta-4 in acute MI patients. Small clinical component, no Phase III data.Chen et al., 2025 in Clinical research publication. View on PubMed
- 8.Review of early clinical development efforts for thymosin beta-4 across wound healing, cardiac, and ophthalmic indications. Documents the stall in Phase III advancement.Kim J et al., 2012 in Expert Opin Investig Drugs. View on PubMed
- 9.Mechanism study showing thymosin beta-4 reduces programmed cell death at the wound edge and accelerates corneal epithelial healing in animal models.Sosne G et al., 2010 in Expert Opin Biol Ther. View on PubMed
- 10.Animal cardiac study linking thymosin beta-4's actin-binding activity with nitric oxide signaling as a mechanism for cardiac repair after injury.Bock-Marquette I et al., 2009 in J Mol Cell Cardiol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.